수의용 약제 감수성 시험 시장 규모, 점유율과 동향 분석 리포트 : 동물별, 제품별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

Veterinary Antimicrobial Susceptibility Testing Market Summary

The veterinary antimicrobial susceptibility testing market size was estimated at USD 1.13 billion in 2024 and is projected to reach USD 2.26 billion by 2033, growing at a CAGR of 8.06% from 2025 to 2033. The market is experiencing growth driven by rising regulatory & training initiatives among leading veterinary organizations, the growing potential of Artificial Intelligence (AI) in AST, growth in companion animal ownership and veterinary care, and growing Antimicrobial Resistance (AMR) among animals.

Veterinary professionals rely on Antimicrobial Susceptibility Testing (AST) to choose the most effective treatment for animal diseases. This testing identifies bacterial pathogens and determines antimicrobial agents that will deliver the best therapeutic outcomes, reducing the risk of antimicrobial resistance (AMR). For instance, in April 2025, Almaty hosted Kazakhstan's first FAO-led veterinary AST training, equipping specialists with international-standard skills to enhance AMR surveillance and strengthen national laboratory capacity, advancing One Health-driven animal and public health security. Such initiatives reinforce countries' laboratory capabilities, aligning veterinary practices with global One Health standards for sustainable health security.

Some of the leading veterinary organizations are driving improvements in AST by releasing standardized reference materials and practical resources. These initiatives empower veterinarians to make data-driven treatment decisions, enhance diagnostic accuracy, and promote responsible antimicrobial use, ultimately improving clinical outcomes and supporting sustainable animal health practices. For instance, in January 2024, the American Veterinary Medical Association (AVMA) strengthened its leadership in antimicrobial stewardship by publishing more than six comprehensive documents on animal antimicrobial susceptibility testing. These resources guide veterinary professionals in selecting the most effective antimicrobial therapies and predicting treatment outcomes for a wide range of bacterial infections.

The documents provide standardized guidelines for assessing pathogen sensitivity and resistance across multiple antimicrobial agents, enabling veterinarians to make rapid, evidence-based decisions for various animal species, including dogs, cats, cattle, poultry, and pigs. In addition, AVMA's antimicrobial stewardship program promotes responsible antimicrobial use, aiming to optimize treatment efficacy, improve patient outcomes, and reduce the spread of antimicrobial resistance and multidrug-resistant infections.

Global Veterinary Antimicrobial Susceptibility Testing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global veterinary antimicrobial susceptibility testing market report based on animal, product, end-use and region:

• Animal Outlook (Revenue, USD Million, 2021-2033)
• Production Animal
  • Cattle
  • Poultry
  • Pigs
  • Others
• Companion Animal
  • Dogs
  • Cats
  • Horses
  • Others
• Product Outlook (Revenue, USD Million, 2021-2033)
• Disks & Plates
• Culture Media
• Accessories & Consumables
• Automated AST Instruments
• End-use Outlook (Revenue, USD Million, 2021-2033)
• Veterinary Reference Lab
• Vet Research Institutes
• Others
• Region Outlook (Revenue, USD Million, 2021-2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait
  • Qatar
  • Oman

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Animal
  • 1.2.3. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information/Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Model 1 Analysis
  • 1.7.2. Model 2 Analysis
  • 1.7.3. Model 3 Analysis
• 1.8. List of Secondary Sources
• 1.9. List of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Market Variable Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary/Related Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing Prevalence of Vector-Borne Diseases
    • 3.2.1.2. Growing Importance of Preventive Care
    • 3.2.1.3. Emergence of Novel FTH Products
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High Costs of Flea, Tick, And Heartworm Products
  • 3.2.3. Market Opportunity Analysis
  • 3.2.4. Market Challenge Analysis
  • 3.2.5. Technology Landscape
• 3.3. Pricing Model Analysis
• 3.4. Estimated Animal Population, By Species, By Region, 2024
• 3.5. Market Analysis Tools
  • 3.5.1. Porter's Five Forces Analysis
  • 3.5.2. PESTEL by SWOT Analysis

Chapter 4. Veterinary Antimicrobial Susceptibility Testing Market: Product Estimates & Trend Analysis

• 4.1. Veterinary Antimicrobial Susceptibility Testing Market, By Product: Segment Dashboard
• 4.2. Veterinary Antimicrobial Susceptibility Testing Market, By Product Movement Analysis
• 4.3. Veterinary Antimicrobial Susceptibility Testing Market Estimates & Forecasts, by Product, 2021 to 2033 (USD Million)
• 4.4. Disks & Plates
  • 4.4.1. Diagnostic Products Market Estimates and Forecasts, 2021 - 2033(USD Million)
• 4.5. Culture Media
  • 4.5.1. Culture Media Market Estimates and Forecasts, 2021 - 2033(USD Million)
• 4.6. Accessories & Consumables
  • 4.6.1. Accessories & Consumables Market Estimates and Forecasts, 2021 - 2033(USD Million)
• 4.7. Automated AST Instruments
  • 4.7.1. Automated AST Instruments Market Estimates and Forecasts, 2021 - 2033(USD Million)

Chapter 5. Veterinary Antimicrobial Susceptibility Testing Market: By Animal Estimates & Trend Analysis

• 5.1. Veterinary Antimicrobial Susceptibility Testing Market, By Animal: Segment Dashboard
• 5.2. Veterinary Antimicrobial Susceptibility Testing Market, By Animal Movement Analysis
• 5.3. Veterinary Antimicrobial Susceptibility Testing Market Estimates & Forecasts, by Animal, 2021 to 2033 (USD Million)
• 5.4. Production Animal
  • 5.4.1. Production Animal Market Estimates and Forecasts, 2021 - 2033(USD Million)
  • 5.4.2. Cattle
    • 5.4.2.1. Cattle Market Estimates and Forecasts, 2021 - 2033(USD Million)
  • 5.4.3. Poultry
    • 5.4.3.1. Poultry Market Estimates and Forecasts, 2021 - 2033(USD Million)
  • 5.4.4. Pigs
    • 5.4.4.1. Pigs Market Estimates and Forecasts, 2021 - 2033(USD Million)
  • 5.4.5. Others
    • 5.4.5.1. Others Market Estimates and Forecasts, 2021 - 2033(USD Million)
• 5.5. Companion Animal
  • 5.5.1. Companion Animal Market Estimates and Forecasts, 2021 - 2033(USD Million)
  • 5.5.2. Dogs
    • 5.5.2.1. Dogs Market Estimates and Forecasts, 2021 - 2033(USD Million)
  • 5.5.3. Cats
    • 5.5.3.1. Cats Market Estimates and Forecasts, 2021 - 2033(USD Million)
  • 5.5.4. Horses
    • 5.5.4.1. Horses Market Estimates and Forecasts, 2021 - 2033(USD Million)
  • 5.5.5. Others
    • 5.5.5.1. Others Market Estimates and Forecasts, 2021 - 2033(USD Million)

Chapter 6. Veterinary Antimicrobial Susceptibility Testing Market: By End Use Estimates & Trend Analysis

• 6.1. Veterinary Antimicrobial Susceptibility Testing Market, By End Use: Segment Dashboard
• 6.2. Veterinary Antimicrobial Susceptibility Testing Market, By End Use Movement Analysis
• 6.3. Veterinary Antimicrobial Susceptibility Testing Market Estimates & Forecasts, by End Use, 2021 to 2033 (USD Million)
• 6.4. Veterinary Reference Laboratories
  • 6.4.1. Veterinary Reference Laboratories Market Estimates and Forecasts, 2021 - 2033(USD Million)
• 6.5. Veterinary Research Laboratories
  • 6.5.1. Veterinary Research Laboratories Market Estimates and Forecasts, 2021 - 2033(USD Million)
• 6.6. Others
  • 6.6.1. Others Market Estimates and Forecasts, 2021 - 2033(USD Million)

Chapter 7. Veterinary Antimicrobial Susceptibility Testing Market: By Regional Estimates & Trend Analysis

• 7.1. Region Market Dashboard
• 7.2. Region Market Share Analysis, 2024 & 2033
• 7.3. North America
  • 7.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.2. U.S
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Competitive Scenario
    • 7.3.2.3. Regulatory Framework
    • 7.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Competitive Scenario
    • 7.3.3.3. Regulatory Framework
    • 7.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.4. Mexico
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Competitive Scenario
    • 7.3.4.3. Regulatory Framework
    • 7.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.4. Europe
  • 7.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.2. UK
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.3. Germany
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Competitive Scenario
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Competitive Scenario
    • 7.4.5.3. Regulatory Framework
    • 7.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Competitive Scenario
    • 7.4.6.3. Regulatory Framework
    • 7.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.7. Denmark
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Competitive Scenario
    • 7.4.7.3. Regulatory Framework
    • 7.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.8. Sweden
    • 7.4.8.1. Key Country Dynamics
    • 7.4.8.2. Competitive Scenario
    • 7.4.8.3. Regulatory Framework
    • 7.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.9. Norway
    • 7.4.9.1. Key Country Dynamics
    • 7.4.9.2. Competitive Scenario
    • 7.4.9.3. Regulatory Framework
    • 7.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. Japan
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. China
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.5. Australia
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Competitive Scenario
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Competitive Scenario
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.7. South Korea
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Latin America
  • 7.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. MEA
  • 7.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.2. South Africa
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.4. Saudi Arabia
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Competitive Scenario
    • 7.7.4.3. Regulatory Framework
    • 7.7.4.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key Country Dynamics
    • 7.7.5.2. Competitive Scenario
    • 7.7.5.3. Regulatory Framework
    • 7.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.6. Qatar
    • 7.7.6.1. Key Country Dynamics
    • 7.7.6.2. Competitive Scenario
    • 7.7.6.3. Regulatory Framework
    • 7.7.6.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.7. Oman
    • 7.7.7.1. Key Country Dynamics
    • 7.7.7.2. Competitive Scenario
    • 7.7.7.3. Regulatory Framework
    • 7.7.7.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Market Participant Categorization
  • 8.1.1. Market Leaders
  • 8.1.2. Emerging Players
• 8.2. Market Share/Assessment Analysis, 2024 (Heat Map Analysis)
• 8.3. Company Profiles
  • 8.3.1. BioMerieux SA
    • 8.3.1.1. Participant's Overview
    • 8.3.1.2. Financial Performance
    • 8.3.1.3. Product/Service Benchmarking
    • 8.3.1.4. Strategic Initiatives
  • 8.3.2. Becton, Dickinson and Company (BD)
    • 8.3.2.1. Participant's Overview
    • 8.3.2.2. Financial Performance
    • 8.3.2.3. Product/Service Benchmarking
    • 8.3.2.4. Strategic Initiatives
  • 8.3.3. Synbiosis
    • 8.3.3.1. Participant's Overview
    • 8.3.3.2. Financial Performance
    • 8.3.3.3. Product/Service Benchmarking
    • 8.3.3.4. Strategic Initiatives
  • 8.3.4. Thermo Fisher Scientific
    • 8.3.4.1. Participant's Overview
    • 8.3.4.2. Financial Performance
    • 8.3.4.3. Product/Service Benchmarking
    • 8.3.4.4. Strategic Initiatives
  • 8.3.5. Bruker Corporation
    • 8.3.5.1. Participant's Overview
    • 8.3.5.2. Financial Performance
    • 8.3.5.3. Product/Service Benchmarking
    • 8.3.5.4. Strategic Initiatives
  • 8.3.6. Mast Group Ltd
    • 8.3.6.1. Participant's Overview
    • 8.3.6.2. Financial Performance
    • 8.3.6.3. Product/Service Benchmarking
    • 8.3.6.4. Strategic Initiatives
  • 8.3.7. Condalab
    • 8.3.7.1. Participant's Overview
    • 8.3.7.2. Financial Performance
    • 8.3.7.3. Product/Service Benchmarking
    • 8.3.7.4. Strategic Initiatives
  • 8.3.8. Bioguard Corporation
    • 8.3.8.1. Participant's Overview
    • 8.3.8.2. Financial Performance
    • 8.3.8.3. Product/Service Benchmarking
    • 8.3.8.4. Strategic Initiatives
  • 8.3.9. Liofilchem S.r.l.
    • 8.3.9.1. Participant's Overview
    • 8.3.9.2. Financial Performance
    • 8.3.9.3. Product/Service Benchmarking
    • 8.3.9.4. Strategic Initiatives
  • 8.3.10. HiMedia Laboratories
    • 8.3.10.1. Participant's Overview
    • 8.3.10.2. Financial Performance
    • 8.3.10.3. Product/Service Benchmarking
    • 8.3.10.4. Strategic Initiatives
  • 8.3.11. Bio-Rad Laboratories
    • 8.3.11.1. Participant's Overview
    • 8.3.11.2. Financial Performance
    • 8.3.11.3. Product/Service Benchmarking
    • 8.3.11.4. Strategic Initiatives